Drug Accountability: An Important Aspect of Clinical ResearchAnand Butani
Drug accountability is an interesting topic related to clinical research, both for the CRAs and for the clinical research sites. Even though drug accountability isn’t a task that should be performed by the CRA, he or she is still responsible for monitoring and making sure that the site is correctly performing every task related to this field.
The topic of drug accountability is especially important in regards to quality data as well as for patient safety. For this reason, we’ll give you an in-depth explanation of everything that drug accountability entails.
What Is IP?
IP/ IMP – Investigational Medical Product
An investigational product refers to a preventative (vaccine), a therapeutic (drug or biologic), device, diagnostic, or palliative used in a clinical trial.
What is IP manufacturing?
IP Manufacturing responsibility lies with the sponsor with any applicable GMP.
Any changes in the investigational or comparator product during the course of clinical development – additional studies need to be check for formulated product whether these changes would significantly alter the pharmacokinetic profile of the product.
What is Labeling?
The IP label contains information on :
Composition
Storage
Requirements, expiration date (if applicable), etc.
Expired and/or un-labelled IP must be quarantined and not to be dispensed.
Explain expiration and retest dates to the subject.
The statement: "For clinical research use only" or similar wording
Siro Clinpharm initiative
www.siroinstitute.com
Post Graduate Diploma in Clinical Research. Pharmacovigilance, Clinical Trials, Clinical Data Management, Clinical Operation, Medical writing.
#Pharmacovigilance #CDM #data #Clinicalresearch, #regulatoryaffairs, #medicalcoding, #clinicalSAS #management #health #comment #pune
#clinicalresearch #medicaldevices #career #opportunity #oncology
#safety #pharmajobs #gpat #pharmacy #mbbs #jobs #jobsearch #training #healthandsafety #nowhiring #healthcare #clinical #opportunities #doctor #medicine #hiring #bpharmajobs #coding #regulatoryaffairs #medical #nursing
#clinicalresearch #medicaldevices #career #opportunity #oncology #safety #pharmajobs #gpat #pharmacy #mbbs #jobs #jobsearch # #training #healthandsafety #nowhiring #healthcare #clinical #opportunities #doctor #medicine #hiring #bpharmajobs #coding #regulatoryaffairs #medical #nursing #pharmacovigilance #statistics #biostatistician #opportunity #interview #biostatistics #statisticalprogramming #team #fresher #project #students #development #projects #work #leaders #people #learning #culture #productivity #leader #event #clinicalresearch #clinicaloperations #clinicaldatamanagement #cdm
#clinicalresearchassociate #clinicalresearchcoordinator #pharmacovigilance ,#medicalcoders ,#sas ,#SASprogrammers #Biosatisticians, #Clinicaltrialdesign, #eTMF #lifescience
#medicaldevices,#scdmindia,#societyforclinicaldata
#lifesciencemanagement,#pharmaceuticals,#medicalwriting
#clinicalresearchinstitute #CRA #CRC #Databasedesign
#pharmacovigilanceindia #CTA #pharmacist #EDC , #GCP #pharmacovigilance #clinicalresearch #quality #clinicalresearchassociate #clinicalresearchcoordinator #clinicalresearchjobs #clinicaltrialmanagement #clinicaltrials #clinicaltraining #pharmacy #pharmacylife #pharmacycollege #pharmaceutical #pharmacist #pharmaindustry
Monitoring plan and basic monitoring visits: everything that a cra needs to knowTrialJoin
A monitor in a clinical trial is also called a CRA - clinical research associate. This person is a professional who’s responsible for monitoring the clinical trial and making sure that everything is according to rules, regulations, and good clinical practice.
Whether you already are a CRA or you’re trying to become one, the most important thing you should be aware of is the monitoring plan. You, as a CRA or a future CRA, should know what a monitoring plan is, what it serves for, and what it consists of. The second most important information for you are the monitoring visits. Below, we’ll explain all the components of a monitoring plan, as well as which are the most basic and important monitoring visits.
Monitoring Plan and Basic Monitoring Visits: Everything that a CRA Needs to KnowAnand Butani
The document discusses the key components of a clinical trial monitoring plan for a clinical research associate (CRA). It outlines the CRA assignments and guidelines, the monitoring visit timeline, and types of visits including pre-study visits, site initiation visits, interim monitoring visits, close-out visits, and pre-audit visits. It also covers traditional versus risk-based monitoring and the knowledge required about investigational products, interactive response systems, problems/adverse events, and shipment/inventory. The goal is to explain everything a CRA needs to know to properly conduct monitoring according to regulations and guidelines.
The drug development process involves 5 main steps: (1) discovery and development through preclinical research on animals, (2) clinical research conducted in 4 phases with human subjects to test safety, efficacy, and side effects, (3) FDA drug review of the New Drug Application and clinical trial data, (4) potential FDA approval or denial, and (5) ongoing FDA post-market drug safety monitoring through manufacturer inspections, surveillance of large electronic health databases, and analysis of reported adverse events. The overall process aims to discover new drugs, understand how they work, ensure they are safe and effective for their intended use through clinical trials, and continuously monitor approved drugs for unexpected safety issues.
Drug accountability is important to ensure proper control, storage, dispensing and handling of investigational drugs according to regulatory standards. Accurate documentation demonstrates that drugs were administered per protocol and supports validity of study data and conclusions. Key aspects to document include drug receipt, dispensing to subjects, returns, inventory and final disposition. Maintaining proper accountability through documentation protects subjects, validates study conduct and ensures regulatory compliance.
The document discusses Good Laboratory Practices (GLP), which are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP was established in response to cases of poor laboratory practices including fraudulent activities and inaccurate reporting of results. The objectives of GLP are to ensure data submitted accurately reflects study results and is traceable. Laboratories must comply with standards for facilities, equipment, record-keeping, personnel qualifications and quality control to avoid penalties for noncompliance like disqualification and inability to conduct future studies.
The document discusses Good Laboratory Practices (GLP), which are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP was established in response to cases of poor laboratory practices including fraudulent activities and inaccurate reporting of results. The objectives of GLP are to ensure data submitted accurately reflects study results and is traceable. Laboratories must comply with requirements around facilities, equipment, recordkeeping, personnel qualifications and standard operating procedures to adhere to GLP. Noncompliance can result in disqualification and civil or criminal penalties for the laboratory.
Drug Accountability: An Important Aspect of Clinical ResearchAnand Butani
Drug accountability is an interesting topic related to clinical research, both for the CRAs and for the clinical research sites. Even though drug accountability isn’t a task that should be performed by the CRA, he or she is still responsible for monitoring and making sure that the site is correctly performing every task related to this field.
The topic of drug accountability is especially important in regards to quality data as well as for patient safety. For this reason, we’ll give you an in-depth explanation of everything that drug accountability entails.
What Is IP?
IP/ IMP – Investigational Medical Product
An investigational product refers to a preventative (vaccine), a therapeutic (drug or biologic), device, diagnostic, or palliative used in a clinical trial.
What is IP manufacturing?
IP Manufacturing responsibility lies with the sponsor with any applicable GMP.
Any changes in the investigational or comparator product during the course of clinical development – additional studies need to be check for formulated product whether these changes would significantly alter the pharmacokinetic profile of the product.
What is Labeling?
The IP label contains information on :
Composition
Storage
Requirements, expiration date (if applicable), etc.
Expired and/or un-labelled IP must be quarantined and not to be dispensed.
Explain expiration and retest dates to the subject.
The statement: "For clinical research use only" or similar wording
Siro Clinpharm initiative
www.siroinstitute.com
Post Graduate Diploma in Clinical Research. Pharmacovigilance, Clinical Trials, Clinical Data Management, Clinical Operation, Medical writing.
#Pharmacovigilance #CDM #data #Clinicalresearch, #regulatoryaffairs, #medicalcoding, #clinicalSAS #management #health #comment #pune
#clinicalresearch #medicaldevices #career #opportunity #oncology
#safety #pharmajobs #gpat #pharmacy #mbbs #jobs #jobsearch #training #healthandsafety #nowhiring #healthcare #clinical #opportunities #doctor #medicine #hiring #bpharmajobs #coding #regulatoryaffairs #medical #nursing
#clinicalresearch #medicaldevices #career #opportunity #oncology #safety #pharmajobs #gpat #pharmacy #mbbs #jobs #jobsearch # #training #healthandsafety #nowhiring #healthcare #clinical #opportunities #doctor #medicine #hiring #bpharmajobs #coding #regulatoryaffairs #medical #nursing #pharmacovigilance #statistics #biostatistician #opportunity #interview #biostatistics #statisticalprogramming #team #fresher #project #students #development #projects #work #leaders #people #learning #culture #productivity #leader #event #clinicalresearch #clinicaloperations #clinicaldatamanagement #cdm
#clinicalresearchassociate #clinicalresearchcoordinator #pharmacovigilance ,#medicalcoders ,#sas ,#SASprogrammers #Biosatisticians, #Clinicaltrialdesign, #eTMF #lifescience
#medicaldevices,#scdmindia,#societyforclinicaldata
#lifesciencemanagement,#pharmaceuticals,#medicalwriting
#clinicalresearchinstitute #CRA #CRC #Databasedesign
#pharmacovigilanceindia #CTA #pharmacist #EDC , #GCP #pharmacovigilance #clinicalresearch #quality #clinicalresearchassociate #clinicalresearchcoordinator #clinicalresearchjobs #clinicaltrialmanagement #clinicaltrials #clinicaltraining #pharmacy #pharmacylife #pharmacycollege #pharmaceutical #pharmacist #pharmaindustry
Monitoring plan and basic monitoring visits: everything that a cra needs to knowTrialJoin
A monitor in a clinical trial is also called a CRA - clinical research associate. This person is a professional who’s responsible for monitoring the clinical trial and making sure that everything is according to rules, regulations, and good clinical practice.
Whether you already are a CRA or you’re trying to become one, the most important thing you should be aware of is the monitoring plan. You, as a CRA or a future CRA, should know what a monitoring plan is, what it serves for, and what it consists of. The second most important information for you are the monitoring visits. Below, we’ll explain all the components of a monitoring plan, as well as which are the most basic and important monitoring visits.
Monitoring Plan and Basic Monitoring Visits: Everything that a CRA Needs to KnowAnand Butani
The document discusses the key components of a clinical trial monitoring plan for a clinical research associate (CRA). It outlines the CRA assignments and guidelines, the monitoring visit timeline, and types of visits including pre-study visits, site initiation visits, interim monitoring visits, close-out visits, and pre-audit visits. It also covers traditional versus risk-based monitoring and the knowledge required about investigational products, interactive response systems, problems/adverse events, and shipment/inventory. The goal is to explain everything a CRA needs to know to properly conduct monitoring according to regulations and guidelines.
The drug development process involves 5 main steps: (1) discovery and development through preclinical research on animals, (2) clinical research conducted in 4 phases with human subjects to test safety, efficacy, and side effects, (3) FDA drug review of the New Drug Application and clinical trial data, (4) potential FDA approval or denial, and (5) ongoing FDA post-market drug safety monitoring through manufacturer inspections, surveillance of large electronic health databases, and analysis of reported adverse events. The overall process aims to discover new drugs, understand how they work, ensure they are safe and effective for their intended use through clinical trials, and continuously monitor approved drugs for unexpected safety issues.
Drug accountability is important to ensure proper control, storage, dispensing and handling of investigational drugs according to regulatory standards. Accurate documentation demonstrates that drugs were administered per protocol and supports validity of study data and conclusions. Key aspects to document include drug receipt, dispensing to subjects, returns, inventory and final disposition. Maintaining proper accountability through documentation protects subjects, validates study conduct and ensures regulatory compliance.
The document discusses Good Laboratory Practices (GLP), which are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP was established in response to cases of poor laboratory practices including fraudulent activities and inaccurate reporting of results. The objectives of GLP are to ensure data submitted accurately reflects study results and is traceable. Laboratories must comply with standards for facilities, equipment, record-keeping, personnel qualifications and quality control to avoid penalties for noncompliance like disqualification and inability to conduct future studies.
The document discusses Good Laboratory Practices (GLP), which are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP was established in response to cases of poor laboratory practices including fraudulent activities and inaccurate reporting of results. The objectives of GLP are to ensure data submitted accurately reflects study results and is traceable. Laboratories must comply with requirements around facilities, equipment, recordkeeping, personnel qualifications and standard operating procedures to adhere to GLP. Noncompliance can result in disqualification and civil or criminal penalties for the laboratory.
Megazyme Inc. is requesting information from Getafix Laboratories to conduct due diligence on Rivatmine, a drug for Alzheimer's patients. They request documents on intellectual property, regulatory status, pre-clinical testing, pharmacology studies, toxicity studies, clinical trials data, manufacturing information, and regulatory filings to evaluate the drug's development and commercial potential. This includes information on patents, marketing authorizations, DMF filings, GLP compliance, pharmacology, genotoxicity tests, PK/PD studies, efficacy tests, chronic toxicity plans, safety pharmacology, carcinogenicity plans, reproductive toxicity, clinical trial protocols, IND application records, and investigator brochures.
HealthOnPhone provides a free online health record management account that allows users to organize, manage, search, and control their medical records and those of their family members from anywhere at any time. It digitizes paper health records so users can easily analyze and share information as needed with doctors and others. All information is securely stored and only shared with user permission to ensure privacy.
Good Laboratory Practices (GLP) are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP aims to ensure study data accurately reflects results and is traceable. The regulations were established in response to discovered fraudulent activities and poor practices in toxicology labs in the 1970s. Facilities that do not comply with GLP standards risk disqualification, meaning they cannot conduct new studies or submit existing ones. Disqualified facilities can apply for reinstatement by demonstrating they will adhere to GLP procedures going forward.
Good Laboratory Practices (GLP) are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP aims to ensure study data accurately reflects results and is traceable. The regulations were established in response to discovered fraudulent activities and poor practices at toxicology labs in the 1970s. Facilities that do not comply with GLP standards risk disqualification, meaning they cannot conduct new studies or submit existing ones. Disqualified facilities can apply for reinstatement by demonstrating they will adhere to GLP procedures going forward.
Fresenius Kabi and Calea UK were fined over $800,000 following the death of a diabetic patient who was injected with an insulin syringe containing no insulin. An investigation found manufacturing deficiencies at their joint facility.
Fresenius Kabi's New York facility also received an FDA warning letter in 2012 for GMP violations, and its India API plant received a letter in 2013 for data manipulation issues.
The FDA warning letter to Fresenius Kabi's India plant outlined issues including testing samples unofficially and ignoring out-of-specification results, combining API batches to meet specifications, incomplete laboratory records, and improper retesting practices. The company also delayed and limited information for FDA investigators during the inspection
GLP refers to Good Laboratory Practice, which are standards set by the FDA for conducting laboratory studies. GLP was created in the late 1970s after investigations found many cases of fraudulent activities and poor practices in toxicology labs. The objectives of GLP are to ensure laboratory data accurately reflects study results and is traceable. Facilities that do not comply with GLP standards risk disqualification, meaning they cannot conduct or submit studies to the FDA. Disqualification can occur if noncompliance affected study validity or a facility failed to improve after warnings.
Data integrity - Regulatory Perspective and Challenges: santoshnarla
This document provides an agenda for a conference on ensuring product quality and patient safety. The agenda includes sessions on data integrity risk management, data integrity in clinical research, data quality management in clinical research, regulations impacting data integrity, creating a culture of quality for data integrity, data management perspectives and challenges for the pharmaceutical MSME sector in India, data integrity from an analytical laboratory perspective, an overview of data integrity non-conformances from regulators, data integrity as an essential part of quality, the regulatory perspective on data integrity and challenges, MHRA and US FDA requirements for data integrity in clinical studies, data integrity on the manufacturing floor, and other topics. Various experts from the pharmaceutical industry will speak in the different sessions.
The document provides information about audits, inspections, and compliance from the perspective of a Contract Research Organization (CRO). It discusses what a CRO is and different types of CROs. It outlines the importance of having a structured compliance plan and ensuring compliance with Good Laboratory/Clinical/Manufacturing Practices, applicable rules, regulations, and guidelines. The document emphasizes that quality control, monitoring, auditing, and inspections are necessary to ensure compliance and pass regulatory inspections. It provides tips for sites on preparing for and handling inspections by regulatory authorities like the FDA.
Hu-Friedy's SporeCheck is an in-office biological monitoring system that provides the fastest results in 24 hours. It includes self-contained steam biological indicators, a record notebook, vial crusher, and dry block incubator. SporeCheck allows dental practices to validate their steam sterilizers are functioning properly in compliance with regulations. The presentation reviewed the steps of using SporeCheck, which involves processing a biological indicator, incubating it, and checking for a color change to determine sterilization results.
The document summarizes the implementation and use of an electronic medical record (EMR) system called Epic across multiple hospitals. It describes how Epic is improving safety by incorporating barcode technology for medication administration. Epic allows physicians to electronically prescribe medications that flow directly to patient charts and pharmacies. Pharmacists verify medication orders and dispense drugs with barcodes that nurses scan during administration to ensure the right patient receives the right drug. The system provides automated checks and records of medication administration. Physicians can also electronically view and update patient records through Epic.
This document discusses the importance of batch tracking and traceability in natural health product distribution. Federal regulations require that manufacturers, packagers, importers, and distributors establish systems to track product batches to enable rapid recall if issues arise. Inaccurate batch picking at distribution centers can compromise recalls and potentially lead to regulatory issues or consumer illness if affected products are not properly traced and located. The document emphasizes that strict adherence to batch tracking from receipt to shipment is vital to protect consumers and comply with regulatory requirements.
This document provides clarification on questions regarding the Good Laboratory Practice (GLP) regulations through consolidating questions the FDA has received and answered over a 2 year period. It relates the questions and answers to the specific provisions in the GLP regulations. This summary is intended to help FDA field investigators and headquarters personnel consistently interpret and apply the GLP regulations during inspections and in operating the GLP compliance program. Laboratories and firms should direct any additional questions to the FDA.
Understanding the Drug Development ProcessEMMAIntl
The FDA’s process for drug development can be a lengthy, and often expensive, commitment. If you are developing a new drug product from the beginning, it is critical that you understand the phases of the development process and the deliverables for each. Beginning with R&D, you will have to ensure that your product corresponds with the FDA’s definition of a drug product. Next, it is advised that you conduct sufficient testing to get a baseline understanding of how your product works, what its intended use is, and other product specifications. Once you have completed this first step, you are ready to embark on the drug development journey...
Flaskdata.io automated monitoring for clinical trialsFlaskdata.io
In the race to deliver a COVID-19 vaccine, technology can be used to automate patient safety monitoring and assure that patients and physicians have valid data in order to make good decisions regarding risks and benefits.
This document provides an orientation on federal and internal licensure exams for pharmacy students in Ethiopia. It discusses the domains and format of the federal exam, including sample multiple choice questions. It also provides feedback on the internal exam components of dispensing, drug supply chain management, and regulatory services. Sample questions are included to assess understanding of good practices in areas like inventory management, dispensing, and pharmaceutical regulation.
FDA Enforcement: What Every Clinical Director Should KnowMichael Swit
Half day tutorial presentation on key compliance concerns for those involved in clinical studies, with an emphasis on the key issues FDA examines and also a review of FDA's enforcement powers, ranging from warning letters to criminal prosecutions.
This presentation discusses various topics related to clinical research management including:
- Preparation of clinical studies according to ICH guidelines.
- The difference between audits and inspections, who conducts them, and what they audit.
- Monitoring clinical studies to ensure adherence to protocols, SOPs, and regulations.
- Pharmacovigilance including adverse event reporting procedures.
- Documentation requirements for clinical research.
- Budgeting considerations for clinical trials including personnel, technology, data management.
- Vendor management activities like contracting, governance, and relationship management.
The 11-step process for how a prescription becomes a labeled bottle at the pharmacy includes:
1) The customer drops off the paper prescription at the pharmacy and provides identifying information.
2) The prescription is scanned into the system and a wait time is provided while the technician processes it.
3) A label is printed and the stock bottle is retrieved and scanned to verify the correct medication.
4) The pharmacist checks the prescription details and bottles it with the correct amount of pills and labeling.
5) When the customer returns, they verify their information and sign to pick up the labeled prescription bottle.
Adverse Drug Reaction (ADR) reporting is a vital process in pharmacovigilance that involves the identification, documentation, and analysis of adverse effects or unexpected reactions to medications. Healthcare professionals, including clinical pharmacists, play a crucial role in reporting ADRs to regulatory authorities. Timely and accurate reporting helps enhance patient safety, contributes to the continuous monitoring of drug safety profiles, and facilitates informed decision-making in healthcare. ADR reporting is a proactive measure to ensure the ongoing assessment and improvement of medication safety for the benefit of patients and the broader healthcare system.
This document provides an overview of urine drug testing (UDT) and the ToxPlus software and services. It discusses what UDT is, the main types of testing, why physicians should conduct UDT on patients, which substances can be tested for, who and when to test, the ToxPlus workflow process, online services provided, CLIA waiver requirements, and reimbursement options for UDT testing and review.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
More Related Content
Similar to Drug accountability an important aspect of clinical research
Megazyme Inc. is requesting information from Getafix Laboratories to conduct due diligence on Rivatmine, a drug for Alzheimer's patients. They request documents on intellectual property, regulatory status, pre-clinical testing, pharmacology studies, toxicity studies, clinical trials data, manufacturing information, and regulatory filings to evaluate the drug's development and commercial potential. This includes information on patents, marketing authorizations, DMF filings, GLP compliance, pharmacology, genotoxicity tests, PK/PD studies, efficacy tests, chronic toxicity plans, safety pharmacology, carcinogenicity plans, reproductive toxicity, clinical trial protocols, IND application records, and investigator brochures.
HealthOnPhone provides a free online health record management account that allows users to organize, manage, search, and control their medical records and those of their family members from anywhere at any time. It digitizes paper health records so users can easily analyze and share information as needed with doctors and others. All information is securely stored and only shared with user permission to ensure privacy.
Good Laboratory Practices (GLP) are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP aims to ensure study data accurately reflects results and is traceable. The regulations were established in response to discovered fraudulent activities and poor practices in toxicology labs in the 1970s. Facilities that do not comply with GLP standards risk disqualification, meaning they cannot conduct new studies or submit existing ones. Disqualified facilities can apply for reinstatement by demonstrating they will adhere to GLP procedures going forward.
Good Laboratory Practices (GLP) are regulations created by the FDA in 1978 that provide a framework for conducting laboratory studies. GLP aims to ensure study data accurately reflects results and is traceable. The regulations were established in response to discovered fraudulent activities and poor practices at toxicology labs in the 1970s. Facilities that do not comply with GLP standards risk disqualification, meaning they cannot conduct new studies or submit existing ones. Disqualified facilities can apply for reinstatement by demonstrating they will adhere to GLP procedures going forward.
Fresenius Kabi and Calea UK were fined over $800,000 following the death of a diabetic patient who was injected with an insulin syringe containing no insulin. An investigation found manufacturing deficiencies at their joint facility.
Fresenius Kabi's New York facility also received an FDA warning letter in 2012 for GMP violations, and its India API plant received a letter in 2013 for data manipulation issues.
The FDA warning letter to Fresenius Kabi's India plant outlined issues including testing samples unofficially and ignoring out-of-specification results, combining API batches to meet specifications, incomplete laboratory records, and improper retesting practices. The company also delayed and limited information for FDA investigators during the inspection
GLP refers to Good Laboratory Practice, which are standards set by the FDA for conducting laboratory studies. GLP was created in the late 1970s after investigations found many cases of fraudulent activities and poor practices in toxicology labs. The objectives of GLP are to ensure laboratory data accurately reflects study results and is traceable. Facilities that do not comply with GLP standards risk disqualification, meaning they cannot conduct or submit studies to the FDA. Disqualification can occur if noncompliance affected study validity or a facility failed to improve after warnings.
Data integrity - Regulatory Perspective and Challenges: santoshnarla
This document provides an agenda for a conference on ensuring product quality and patient safety. The agenda includes sessions on data integrity risk management, data integrity in clinical research, data quality management in clinical research, regulations impacting data integrity, creating a culture of quality for data integrity, data management perspectives and challenges for the pharmaceutical MSME sector in India, data integrity from an analytical laboratory perspective, an overview of data integrity non-conformances from regulators, data integrity as an essential part of quality, the regulatory perspective on data integrity and challenges, MHRA and US FDA requirements for data integrity in clinical studies, data integrity on the manufacturing floor, and other topics. Various experts from the pharmaceutical industry will speak in the different sessions.
The document provides information about audits, inspections, and compliance from the perspective of a Contract Research Organization (CRO). It discusses what a CRO is and different types of CROs. It outlines the importance of having a structured compliance plan and ensuring compliance with Good Laboratory/Clinical/Manufacturing Practices, applicable rules, regulations, and guidelines. The document emphasizes that quality control, monitoring, auditing, and inspections are necessary to ensure compliance and pass regulatory inspections. It provides tips for sites on preparing for and handling inspections by regulatory authorities like the FDA.
Hu-Friedy's SporeCheck is an in-office biological monitoring system that provides the fastest results in 24 hours. It includes self-contained steam biological indicators, a record notebook, vial crusher, and dry block incubator. SporeCheck allows dental practices to validate their steam sterilizers are functioning properly in compliance with regulations. The presentation reviewed the steps of using SporeCheck, which involves processing a biological indicator, incubating it, and checking for a color change to determine sterilization results.
The document summarizes the implementation and use of an electronic medical record (EMR) system called Epic across multiple hospitals. It describes how Epic is improving safety by incorporating barcode technology for medication administration. Epic allows physicians to electronically prescribe medications that flow directly to patient charts and pharmacies. Pharmacists verify medication orders and dispense drugs with barcodes that nurses scan during administration to ensure the right patient receives the right drug. The system provides automated checks and records of medication administration. Physicians can also electronically view and update patient records through Epic.
This document discusses the importance of batch tracking and traceability in natural health product distribution. Federal regulations require that manufacturers, packagers, importers, and distributors establish systems to track product batches to enable rapid recall if issues arise. Inaccurate batch picking at distribution centers can compromise recalls and potentially lead to regulatory issues or consumer illness if affected products are not properly traced and located. The document emphasizes that strict adherence to batch tracking from receipt to shipment is vital to protect consumers and comply with regulatory requirements.
This document provides clarification on questions regarding the Good Laboratory Practice (GLP) regulations through consolidating questions the FDA has received and answered over a 2 year period. It relates the questions and answers to the specific provisions in the GLP regulations. This summary is intended to help FDA field investigators and headquarters personnel consistently interpret and apply the GLP regulations during inspections and in operating the GLP compliance program. Laboratories and firms should direct any additional questions to the FDA.
Understanding the Drug Development ProcessEMMAIntl
The FDA’s process for drug development can be a lengthy, and often expensive, commitment. If you are developing a new drug product from the beginning, it is critical that you understand the phases of the development process and the deliverables for each. Beginning with R&D, you will have to ensure that your product corresponds with the FDA’s definition of a drug product. Next, it is advised that you conduct sufficient testing to get a baseline understanding of how your product works, what its intended use is, and other product specifications. Once you have completed this first step, you are ready to embark on the drug development journey...
Flaskdata.io automated monitoring for clinical trialsFlaskdata.io
In the race to deliver a COVID-19 vaccine, technology can be used to automate patient safety monitoring and assure that patients and physicians have valid data in order to make good decisions regarding risks and benefits.
This document provides an orientation on federal and internal licensure exams for pharmacy students in Ethiopia. It discusses the domains and format of the federal exam, including sample multiple choice questions. It also provides feedback on the internal exam components of dispensing, drug supply chain management, and regulatory services. Sample questions are included to assess understanding of good practices in areas like inventory management, dispensing, and pharmaceutical regulation.
FDA Enforcement: What Every Clinical Director Should KnowMichael Swit
Half day tutorial presentation on key compliance concerns for those involved in clinical studies, with an emphasis on the key issues FDA examines and also a review of FDA's enforcement powers, ranging from warning letters to criminal prosecutions.
This presentation discusses various topics related to clinical research management including:
- Preparation of clinical studies according to ICH guidelines.
- The difference between audits and inspections, who conducts them, and what they audit.
- Monitoring clinical studies to ensure adherence to protocols, SOPs, and regulations.
- Pharmacovigilance including adverse event reporting procedures.
- Documentation requirements for clinical research.
- Budgeting considerations for clinical trials including personnel, technology, data management.
- Vendor management activities like contracting, governance, and relationship management.
The 11-step process for how a prescription becomes a labeled bottle at the pharmacy includes:
1) The customer drops off the paper prescription at the pharmacy and provides identifying information.
2) The prescription is scanned into the system and a wait time is provided while the technician processes it.
3) A label is printed and the stock bottle is retrieved and scanned to verify the correct medication.
4) The pharmacist checks the prescription details and bottles it with the correct amount of pills and labeling.
5) When the customer returns, they verify their information and sign to pick up the labeled prescription bottle.
Adverse Drug Reaction (ADR) reporting is a vital process in pharmacovigilance that involves the identification, documentation, and analysis of adverse effects or unexpected reactions to medications. Healthcare professionals, including clinical pharmacists, play a crucial role in reporting ADRs to regulatory authorities. Timely and accurate reporting helps enhance patient safety, contributes to the continuous monitoring of drug safety profiles, and facilitates informed decision-making in healthcare. ADR reporting is a proactive measure to ensure the ongoing assessment and improvement of medication safety for the benefit of patients and the broader healthcare system.
This document provides an overview of urine drug testing (UDT) and the ToxPlus software and services. It discusses what UDT is, the main types of testing, why physicians should conduct UDT on patients, which substances can be tested for, who and when to test, the ToxPlus workflow process, online services provided, CLIA waiver requirements, and reimbursement options for UDT testing and review.
Similar to Drug accountability an important aspect of clinical research (20)
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
2. Introduction
Drug accountability is an interesting topic related to
clinical research, both for the CRAs and for the clinical
research sites. Even though drug accountability isn’t a
task that should be performed by the CRA, he or she
is still responsible for monitoring and making sure
that the site is correctly performing every task related
to this field.
The topic of drug accountability is especially
important in regards to quality data as well as for
patient safety. For this reason, we’ll give you an
in-depth explanation of everything that drug
accountability entails.
2
3. www.trialjoin.com
What is an IP?
In clinical research, IP stands for
Investigational Product.
The investigational product is the product
that’s being tested - it can be either the
actual active ingredient or a placebo
(depending on the nature of the study).
3
5. Receiving the Study
Drug and IVRS/IWRS
Placing the IP in a Locked
Cabinet/Storage
The drug accountability process
starts even before randomization.
More specifically, it starts as soon
as the site receives the IP. Once the
drugs are received, the site
coordinator has to log in to IVRS
(Interactive Voice Response System)
or IWRS (Interactive Web Response
System), take the shipment
document, and manually check if all
the units stated in the document
are actually in the delivered box
(bottles, etc.) and that they aren’t
damaged.
Step
1
Step
2
www.trialjoin.com
Every research site should
have a locked cabinet with
the appropriate temperature
adjustments for keeping the
investigational drug. So,
after making sure that all the
drugs delivered, place them
in your locked cabinet.
5
6. www.trialjoin.com
When it’s time to randomize the
subjects, log in to the IWRS, follow the
instructions on their website, and start
randomizing the subjects. After one
subject is randomized, the website will
give you a number which refers to the
subject’s number for the IP he/she
received on that specific visit. This
number should be then logged into
your IP accountability log in the
specific blank space. After this is done,
you (as the site coordinator) will go to
your drug storage/cabinet, find the
appropriate bottle/unit of IP
(according to the same number) and
give it to the subject.
Subject RandomizationStep
4
IP Accountability Log Step
3
After you’ve placed the drug
in the locked cabinet/storage,
you’ll fill out and keep an IP
accountability log in a
separate binder. Here, you
will manually enter every
number from every
bottle/unit of IP. After this is
done you will have a list with
all the units of IP. The rest of
the log will be left blank for
now because the product is
still not dispensed to
subjects.
6
7. www.trialjoin.com
The IP bottle/unit should
be returned to the site
regardless of whether it’s
completely empty or not.
Once the subject returns
the IP unit, you will enter
the number of returned
pills and the date they
were returned in your IP
accountability log.
Returning of the IP
Step
5
7
8. 01 02
06 07
03 04
0805
IP number of every
single unit/bottle
Date when the IP is
received
Date when the IP is
assigned to a subject
Which IP is assigned
to which subject
How many pills were
assigned to each
subject
Date of return of the
IP
How many pills/units
of IP were returned
IP that’s returned to
the sponsor/CRO at
the end of the study
and date
8
www.trialjoin.com
A filled out IP accountability log should give you the following information:
9. The Importance of Logging Data On Time
Maintaining and entering data in the IP log should
always be done regularly and on time. Many
coordinators forget to enter this data and when this
happens, it can really quickly become a huge mess.
After some time has passed, you won’t remember
which IP is dispensed to which subject. This will
make it really hard to keep track of the IP. For this
reason, it’s important to log in this data anytime
someone takes or returns an IP.
www.trialjoin.com
9
10. Close-Out Visit
When the study ends, it’s time for a close-out
visit.
On this visit, all your IP should be accounted for.
You should have a completely filled out IP
accountability log, returned (opened) bottles of
used drugs, and unused (closed) drug units that
weren’t assigned to any subjects.
The returned (used) units of IP and the unused
ones will then be shipped back to the sponsor or
CRO, and in the IP log you will fill out the
appropriate field for this.
www.trialjoin.com
10
11. www.trialjoin.com
CRAs and Drug Accountability
As we mentioned before, the CRA is only the monitor
of the study. This means that he or she is not
responsible for any of the steps explained above.
The CRA will be there to only monitor that the site is
doing this drug accountability and that they’re doing it
correctly and accurately. One of the most important
tasks of a CRA when it comes to drug accountability is
to make sure that the IP log is constantly and properly
maintained and kept up-to-date. After the study ends,
on the close-out visit, the CRA (monitor) will ship the
used and unused units of IP back to the sponsor or
the CRO.
11
12. FDA warning letters for drug accountability failures
Usually, the FDA will come for a drug accountability
inspection at your site. Here, they will check and
control if all of your drug accountability processes
and activities are accurate.
If they see that the site fails to comply with all drug
accountability rules and regulations, they will send
you a warning letter.
www.trialjoin.com
12
13. www.trialjoin.com
Records of incomplete
and/or incorrect
distribution
An adequate
inventory of drugs
was not
maintained so now
records do not
identify recipients
of a particular
batch of the drug
There’s a lack of drug
accountability
registries in relation
to drug transfer
between sites
Not keeping records
of drug distribution
during the study
Shipping invoices
and dispensing
records that in
comparison show
more drugs being
administered than
originally received
You can receive an FDA Warning Letter some of the following problems have been found at your site:
14. www.trialjoin.com
Issues between forms
of drug administration
and accountability
Non-availability of
dispensing drug
records
Study medication
that is missing or not
accounted for
Inaccurate and/or
inadequate source
documents
The CRO failed to
properly supervise
the clinical trial and
ensure compliance
or stopping of
unreliable clinical
investigators
You can receive an FDA Warning Letter some of the following problems have been found at your site:
15. www.trialjoin.com
CONCLUSION
To sum up, drug accountability is an important field in clinical research that will allow you to properly keep track of
every single unit of IP. By doing this task correctly and promptly, you will manage to save yourself a lot of time during
the close-out visit, avoid confusion, and improve data integrity and quality. Furthermore, remember that drug
accountability is a task that belongs to the site (usually the site coordinator), not to the CRA. The CRA will only be there
to monitor and make sure that you’re performing these tasks properly. And finally, the most important part of this
whole thing is the IP accountability log. Make sure to fill this out as soon as your IP arrives, and every time a subject
takes or returns the IP. Like this, you will have a clear and completely filled out accountability log which will provide you
with a better outlook on the whole picture. Drug accountability is one of the most important things in clinical research
since it can greatly influence the quality and integrity of study data and results.
15